Growth hormone, insulin-like growth factor-I and its binding proteins in the follow-up of acromegaly.
Elevated growth hormone is a cardinal feature of acromegaly from the biological view point. Growth hormone stimulates IGF-I secretion and that of its major binding protein IGFBP-3. In these circumstances, where hyperinsulinaemia is present, IGFBP-1 levels, which are inversely related to insulin, are suppressed. Failure of suppression of growth hormone after oral glucose (> 2 mU/l (1 microgram/l) is the cardinal biochemical feature of acromegaly. IGF-I values at diagnosis are almost invariably raised. There is some overlap in the value of basal IGFBP-3 between normal subjects and acromegalics. For monitoring purposes, growth hormone values, either basal or during the day are useful. There is overlap in the values of IGF-I and IGFBP-3 between normal subjects and patients on treatment. Prognosis in acromegaly is determined by persistent elevation of growth hormone levels above 5 mU/l (2.5 micrograms/ l). More data are required for the prognostic use of IGF-I.
Wass
J A
JA
Department of Endocrinology, Radcliffe Infirmary, Oxford, UK.
D000172:Acromegaly / Q000097:blood / Q000175:diagnosis*; D015415:Biomarkers / Q000097:blood; D018450:Disease Progression; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000032:analysis*; D011379:Prognosis
D015415:Biomarkers; D018972:Insulin-Like Growth Factor Binding Protein 3; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone